Sutro Biopharma (STRO) Revenue (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Revenue data on file, last reported at $6.6 million in Q4 2025.

• For the quarter ending Q4 2025, Revenue fell 55.43% year-over-year to $6.6 million; the trailing twelve-month figure through Dec 2025 stood at $97.4 million (up 57.05% YoY), and the FY2025 full-year result was $102.5 million, up 65.18% from the prior year.
• Revenue slipped to $6.6 million in Q4 2025, from $9.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $113.7 million in Q4 2023 to a low of $5.9 million in Q1 2022.
• A 5-year average of $22.1 million and a median of $13.8 million in 2021 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 1217.44% in 2023 and plunged 86.98% in 2024, its largest moves.
• Tracing STRO's Revenue over 5 years: stood at $10.7 million in 2021, then dropped by 18.98% to $8.6 million in 2022, then soared by 1217.44% to $113.7 million in 2023, then sank by 86.98% to $14.8 million in 2024, then slumped by 55.43% to $6.6 million in 2025.
• Business Quant data shows STRO's Revenue at $6.6 million in Q4 2025, $9.7 million in Q3 2025, and $63.7 million in Q2 2025.